Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Reproduction, Fertility and Development Reproduction, Fertility and Development Society
Vertebrate reproductive science and technology
RESEARCH ARTICLE

118 Superovulatory response and embryo production in beef cows treated with a recombinant human FSH

E. Ponte A B , J. A. Sola A , A. Tribulo A C , J. M. Oviedo A , P. Tribulo E F , D. Beltramo D , R. J. Tribulo A and H. E. Tribulo A
+ Author Affiliations
- Author Affiliations

A Instituto de Reproducción Animal Córdoba, Córdoba, Argentina

B Universidad Nacional de Rosario, Facultad de Ciencias Veterinarias, Casilda, Santa Fe, Argentina

C Universidad Nacional de La Rioja, Facultad de Veterinaria, Chamical, La Rioja, Argentina

D Ceprocor, Córdoba, Argentina

E Universidad Nacional de Córdoba, Facultad de Ciencias Agropecuarias, Córdoba, Argentina

F Concejo Nacional de Investigaciones de Ciencia y Técnica, Argentina

Reproduction, Fertility and Development 36(2) 211-212 https://doi.org/10.1071/RDv36n2Ab118

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of the IETS

The aim of the present study was to evaluate the superovulatory response and in vivo embryo production in beef cows treated with a recombinant human FSH (r-hFSH, Nanopharma). Multiparous, nonlactating, cycling Brangus and Braford (Bos indicus influenced, n = 12) and Bonsmara and Angus (Bos taurus, n = 6) cows and with a body condition between 3 and 4 (scale 1–5) were randomly allocated into two treatment groups (r-hFSH or pFSH) and superovulated twice in a crossover design, to avoid individual animal variation. On Day 0, all donors received a progesterone-impregnated intravaginal device (Pluselar 1.2, Calier), along with 5 mg of oestradiol-17β (17β oestradiol) and 50 mg of injectable progesterone (Progesterona) intramuscularly (im). Superstimulatory treatments were initiated on Day 4 and the total dosage of r-hFSH or pFSH administered was based on the manufacturer’s recommendation for each biotype (Bos indicus: 300–500 IU, Bos taurus: 500 IU). For both groups, the treatments were carried out by dividing the total dosage in a decreasing way, divided into 8 injections given 12 h apart. All donors received 150 µg of D (+) Cloprostenol (Ciclar, Zoovet-Ceva) in the morning and afternoon of Day 6. On Day 7 in the afternoon the intravaginal device was removed, and all cows received 20 µg of buserelin acetate (Pluserelina, Calier) on Day 8 in the morning and were inseminated 12 and 24 h later with semen from bulls of proven fertility. Ova/embryos were collected on Day 15 and evaluated according to the IETS and the superovulatory response was evaluated by the number of follicles >9 mm in diameter on Day 8, and the number of corpus luteum (CL) and large (>10 mm) follicles on Day 15, determined by ultrasonography. Data were analysed using the GLMM procedure for a Poisson distribution. The fixed variable was treatment and breed. Cow (id) was a random effect. Although, the number CL and ova/embryos collected, fertilized ova and transferable embryos were greater for the donors treated with pFSH, the number of grade 1 embryos was not different among groups. Furthermore, the number of large follicles on Day 15 was greater in cows treated with r-FSH. There was no effect of breed or a breed by treatment interaction in any of the end points evaluated. In conclusion, p-FSH induced a greater superovulatory response and a tendency for more transferable embryos than r-hFSH. Nevertheless, r-hFSH was effective in inducing a superovulatory response in beef donors and these results warrant further investigation on dose titration.

Table 1.Superovulatory response and in vivo embryo production (means ± standard error) in Bos taurus and Bos indicus donors treated with recombinant human FSH (r-hFSH) or pFSH

TreatmentnFollicles >9 mm on Day 8CLLarge follicles Day 15Ova/embryosFertilized ovaGrade 1 embryosTransferable embryos
p-FSH1711.41 ± 3.3412.74 ± 1.772.59 ± 0.538.19 ± 1.795.53 ± 1.153.76 ± 0.954.71 ± 1.19
r-hFSH179.53 ± 1.669.76 ± 1.243.06 ± 0.906.06 ± 1.264.94 ± 0.572.88 ± 0.573.47 ± 0.81
P-value0.090.01< 0.00010.020.020.160.08